Azitra (AZTR) Receivables - Net (2022 - 2026)

Azitra's (AZTR) quarterly Receivables - Net came in at $5108.0 in Q1 2026, up 460.09% on a QoQ basis from $912.0 in Q4 2025.

Azitra (AZTR) Receivables - Net (2022 - 2026) Analysis & Trends

Azitra (AZTR) has 5 years of Receivables - Net data on file, last reported at $5108.0 in Q1 2026.

Quarterly Receivables - Net changed N/A year-over-year to $5108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5108.0 (changed N/A YoY) and the FY2025 annual result came in at $912.0, up 291.42% from the prior year.
Receivables - Net improved to $5108.0 in Q1 2026, from $912.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $445120.0 in Q2 2023 to a low of $233.0 in Q4 2024.
A 5-year average of $79701.2 and a median of $3482.5 in 2024 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2024 — Receivables - Net plunged 99.75% — and 2025, when it soared 291.42%.
Tracing AZTR's Receivables - Net over 5 years: stood at $175000.0 in 2022, then plunged by 95.28% to $8255.0 in 2023, then plunged by 97.18% to $233.0 in 2024, then soared by 291.42% to $912.0 in 2025, then surged by 460.09% to $5108.0 in 2026.
The last three Receivables - Net figures came in at $5108.0 (Q1 2026), $912.0 (Q4 2025), and $233.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.33 Bn	78.34 Bn	3.93 Bn
3	Argenx Se	65.13 Bn	59.95 Bn	1.37 Bn
4	Moderna	60.47 Bn	55.33 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.04 Bn	27.73 Bn	992.69 Mn
7	BioNTech SE	28.48 Bn	10.09 Bn	668.28 Mn
8	Insmed	27.36 Bn	26.20 Bn	358.27 Mn
9	Royalty Pharma	27.23 Bn	26.39 Bn	-
10	Azitra	2.69 Mn	2.69 Mn	-

Download Data